Astec LifeSciences · NSE: ASTEC · BSE: 533138
Q3 FY20 results · Oct–Dec 2019
Astec LifeSciences reported revenue from operations of ₹124.83 crore (up 4.5% from Q3 FY19) and net profit of ₹12.17 crore (up 21.9% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 124.83 | 119.43 | +4.5% | 140.21 | −11.0% |
| Other income | 3.93 | 3.07 | +28.0% | 1.82 | +115.8% |
| Total income | 128.76 | 122.50 | +5.1% | 142.04 | −9.3% |
| Profit before tax | 15.61 | 15.33 | +1.8% | 7.83 | +99.4% |
| Net profit for the period | 12.17 | 9.98 | +21.9% | 5.29 | +130.1% |
| EPS, basic (₹) | 6.22 | 5.10 | +22.0% | 2.70 | +130.4% |
| Net margin (%) | 9.7 | 8.4 | 3.8 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 124.83 | 119.43 | +4.5% | 140.21 | −11.0% |
| Other income | 3.93 | 3.03 | +29.6% | 1.82 | +115.8% |
| Total income | 128.76 | 122.46 | +5.1% | 142.04 | −9.3% |
| Profit before tax | 15.59 | 15.28 | +2.0% | 7.81 | +99.7% |
| Net profit for the period | 12.15 | 9.94 | +22.3% | 5.27 | +130.5% |
| EPS, basic (₹) | 6.21 | 5.09 | +22.0% | 2.70 | +130.0% |
| Net margin (%) | 9.7 | 8.3 | 3.8 |
Consolidated
- Filed with BSE
- 31 Jan 2020, 15:20 IST
- Board meeting
- 30 Jan 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 31 Jan 2020, 15:20 IST
- Board meeting
- 30 Jan 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE